<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018446</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-SCT-0802</org_study_id>
    <nct_id>NCT01018446</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling</brief_title>
  <official_title>Determination of Optimal Busulfan Dose Using Pharmacokinetic Modeling in Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators plan to develop a method to determine optimal busulfan dose
      through pharmacokinetic study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of
      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity
      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or
      relapse. In this study we plan to develop a method to determine optimal busulfan dose through
      pharmacokinetic study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.</measure>
    <time_frame>For 4 days used Buslufan through pharmacokinetic study in hematopoietic stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate survival, toxicities, engraftment rate of patients received optimal dose of busulfan.</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Busulfan, Pharmacokinetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
    <arm_group_label>Busulfan, Pharmacokinetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hematopoietic stem cell transplantation with busulfan based conditioning

          2. Age: no limits.

          3. Performance status: ECOG 0-2.

          4. Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases. 1. Heart: a
             shortening fraction &gt; 30% and ejection fraction &gt; 45%. 2. Liver: total bilirubin &lt; 2 ×
             upper limit of normal; ALT &lt; 3 × upper limit of normal. 3. Kidney: creatinine &lt;2 ×
             normal or a creatinine clearance (GFR) &gt; 60 ml/min/1.73m2.

          5. Patients must lack any active viral infections or active fungal infection.

          6. Appropriate donor is available: Matched in 6/6 of A, B, DR loci.

          7. Patients (or one of parents if patients age &lt; 19) should sign informed consent.

        Exclusion Criteria:

          1. Pregnant or nursing women.

          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be
             jeopardized by complications of study therapy.

          3. Psychiatric disorder that would preclude compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehangno, Jongno-gu</state>
        <zip>101</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>November 17, 2013</last_update_submitted>
  <last_update_submitted_qc>November 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Korea National Enterprise for Clinical Trials</name_title>
    <organization>Korea National Enterprise for Clinical Trials</organization>
  </responsible_party>
  <keyword>Hematopoietic stem cell transplantation with busulfan based conditioning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

